What are the key takeaways from this The Bio Report episode?

Key insights include: **Anchor Editing Strategy:** Rheumagen's platform targets asparagine at position 82, a conserved site present across all HLA class II alleles. Swapping this amino acid disrupts hydrogen bonding required for peptide presentation, effectively silencing one disease-linked HLA allele while leaving the remaining 11–12 alleles intact to maintain normal immune defense against pathogens.; **Non-Myeloablative Outpatient Delivery:** Unlike traditional bone marrow transplants requiring full myeloablation, Rheumagen's ex vivo stem cell editing requires only minimal bone marrow space-clearing. The therapy is designed for outpatient infusion centers—similar to where RA patients receive biologic infusions—reducing procedural risk and cost compared to hospital-based cell and gene therapy protocols.; **Tipping Point Threshold for Cure:** Full stem cell replacement is not required for clinical benefit. Replacing approximately 90% of hematopoietic stem cells likely produces equivalent disease reduction, and a residual low-level T cell signal can become tolerogenic—essentially training the immune system to ignore self-antigens—potentially crossing a threshold to complete, medication-free remission.

What did Richard Fried discuss on The Bio Report?

Rheumagen CEO Richard Fried explains how the company's HLA gene editing platform targets the genetic root of autoimmune diseases. Rather than suppressing the immune system broadly, Rheumagen edits a single amino acid position in hematopoietic stem cells to permanently silence disease-triggering antigen presentation, beginning with rheumatoid arthritis. Key topics include: **Anchor Editing Strategy:** Rheumagen's platform targets asparagine at position 82, a conserved site present across all HLA class II alleles. Swapping this amino acid disrupts hydrogen bonding required for peptide presentation, effectively silencing one disease-linked HLA allele while leaving the remaining 11–12 alleles intact to maintain normal immune defense against pathogens.; **Non-Myeloablative Outpatient Delivery:** Unlike traditional bone marrow transplants requiring full myeloablation, Rheumagen's ex vivo stem cell editing requires only minimal bone marrow space-clearing. The therapy is designed for outpatient infusion centers—similar to where RA patients receive biologic infusions—reducing procedural risk and cost compared to hospital-based cell and gene therapy protocols..

How long is this episode of The Bio Report?

This episode is 37 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

The Bio Report

Editing Away Autoimmunity at the HLA Source

March 11, 2026

37 min episode · 2 min read

Richard Fried

Episode

37 min

Read time

2 min

Topics

Health & Wellness, Investing, Leadership

AI-Generated Summary

Published Mar 13, 2026

Key Takeaways

✓Anchor Editing Strategy: Rheumagen's platform targets asparagine at position 82, a conserved site present across all HLA class II alleles. Swapping this amino acid disrupts hydrogen bonding required for peptide presentation, effectively silencing one disease-linked HLA allele while leaving the remaining 11–12 alleles intact to maintain normal immune defense against pathogens.
✓Non-Myeloablative Outpatient Delivery: Unlike traditional bone marrow transplants requiring full myeloablation, Rheumagen's ex vivo stem cell editing requires only minimal bone marrow space-clearing. The therapy is designed for outpatient infusion centers—similar to where RA patients receive biologic infusions—reducing procedural risk and cost compared to hospital-based cell and gene therapy protocols.
✓Tipping Point Threshold for Cure: Full stem cell replacement is not required for clinical benefit. Replacing approximately 90% of hematopoietic stem cells likely produces equivalent disease reduction, and a residual low-level T cell signal can become tolerogenic—essentially training the immune system to ignore self-antigens—potentially crossing a threshold to complete, medication-free remission.
✓Regulatory Platform Designation Pathway: Because anchor editing targets the same position 82 across all indications, the FDA's platform designation allows Rheumagen to demonstrate safety once in humans, then advance directly to Phase 2 efficacy trials in subsequent indications including MS and type 1 diabetes, bypassing repeated Phase 1 safety work for each disease.
✓Economic Disruption of Chronic Care Spend: RA patients currently spend $50,000–$60,000 annually on biologics alone, with 60% never reaching remission and 20–30% classified as refractory after failing multiple drugs. A one-time curative therapy with a two-to-four-year payer payback period replaces ongoing chronic spend, repositioning the therapy as a healthcare investment rather than an incremental cost.

What It Covers

Rheumagen CEO Richard Fried explains how the company's HLA gene editing platform targets the genetic root of autoimmune diseases. Rather than suppressing the immune system broadly, Rheumagen edits a single amino acid position in hematopoietic stem cells to permanently silence disease-triggering antigen presentation, beginning with rheumatoid arthritis.

Key Questions Answered

•Anchor Editing Strategy: Rheumagen's platform targets asparagine at position 82, a conserved site present across all HLA class II alleles. Swapping this amino acid disrupts hydrogen bonding required for peptide presentation, effectively silencing one disease-linked HLA allele while leaving the remaining 11–12 alleles intact to maintain normal immune defense against pathogens.
•Non-Myeloablative Outpatient Delivery: Unlike traditional bone marrow transplants requiring full myeloablation, Rheumagen's ex vivo stem cell editing requires only minimal bone marrow space-clearing. The therapy is designed for outpatient infusion centers—similar to where RA patients receive biologic infusions—reducing procedural risk and cost compared to hospital-based cell and gene therapy protocols.
•Tipping Point Threshold for Cure: Full stem cell replacement is not required for clinical benefit. Replacing approximately 90% of hematopoietic stem cells likely produces equivalent disease reduction, and a residual low-level T cell signal can become tolerogenic—essentially training the immune system to ignore self-antigens—potentially crossing a threshold to complete, medication-free remission.
•Regulatory Platform Designation Pathway: Because anchor editing targets the same position 82 across all indications, the FDA's platform designation allows Rheumagen to demonstrate safety once in humans, then advance directly to Phase 2 efficacy trials in subsequent indications including MS and type 1 diabetes, bypassing repeated Phase 1 safety work for each disease.
•Economic Disruption of Chronic Care Spend: RA patients currently spend $50,000–$60,000 annually on biologics alone, with 60% never reaching remission and 20–30% classified as refractory after failing multiple drugs. A one-time curative therapy with a two-to-four-year payer payback period replaces ongoing chronic spend, repositioning the therapy as a healthcare investment rather than an incremental cost.

Notable Moment

For roughly 40 years, immunology held that any HLA modification triggers rejection—the same principle underlying organ transplant matching. Rheumagen's founders, who perform Colorado's transplant HLA matching, identified that edits buried deep within the HLA groove remain invisible to T cells, overturning that foundational assumption entirely.

Know someone who'd find this useful?

Episode Transcript

I'm Daniel Levine, and this is the Bio Report. Human leukocyte antigen or HLA genes help the immune system tell the difference between the body's own tissues and outside threats. In some people, certain versions of HLA genes mistakenly flag normal proteins as dangerous which can push the immune cells to attack joints, nerves, the gut, or other organs. Most autoimmune diseases are driven by changes in HLA genes. Rheumagen is developing a new kind of gene editing treatment that aims to cure autoimmune diseases by going after one of their root genetic triggers. Instead of broadly weakening the immune system, the company's goal is to switch off a single bad version of an immune gene while leaving the rest of the body's defenses intact. We spoke to Richard Fried, CEO of Rumigen, about the role of HLA genes and autoimmune diseases, how the company's gene editing therapies work, and its lead program in rheumatoid arthritis. Richard, thanks for joining us. Oh, Oh, it's a pleasure. Thanks for having me. We're gonna talk about human leukocyte antigens or HLA, their role in autoimmune diseases, and Rubigen's efforts to develop HLA gene editing therapies designed to cure these conditions. Let's start with human leukocyte antigens. Can you explain what these are and the role they play in the immune system? So at Rumigen, we are editing the HLA gene. So the HLA gene or the immune gene codes for these proteins that sit on the surface of all of our cells. And their job, these HLA proteins, their job is to present peptides to, to T cells to start the immune response. Usually, it's viruses or something foreign that they're they're saying this doesn't belong here. Let's show this to T cells. There are tens of thousands of different HLA alleles out there or flavors. Right? Each of us has about a dozen, which makes up our own, you know, unique flavor profile, if you will. And normally, when they present viruses to, to start the T cell activation, that's what you're looking for. But when you have an autoimmune disease, it, they mistakenly start presenting something of your own as foreign. For example, in case of rheumatoid arthritis, it's the collagen in your joints or in MS. One of them is the myelin in your nerve. Right? It's been very well known for many years that certain HLA types are highly prone, highly linked to certain autoimmune diseases, and others are highly, protective. But, nobody really knew why. And that's kind of how we, that was sort of the the beginning of this of this research was, was digging in a little bit deeper of what makes, what makes you susceptible versus protected to different autoimmune diseases. What role do they play in autoimmune diseases? Is there some dysfunction or problem with HLA genes that underlie these conditions? Yeah. So of the tens of thousands of alleles out there, there's only really, call it a few dozen HLA alleles that …

Get the full transcript (5,833 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Bio Report transcripts →